Introduction {#Sec1}
============

Immunoglobulin A nephropathy (IgAN), characterized by the predominant deposition of IgA in the mesangium, is the most frequent primary glomerulonephritis worldwide as well as constituting ≥ 30 % of adult chronic glomerulonephritis in Japan \[[@CR1], [@CR2]\]. The slow progression to end-stage renal disease is known to occur in up to 30--40 % of patients within 20 years \[[@CR3]\]. However, a variety of clinical and pathological features emerge while its prognosis varies greatly from case to case. An effective therapeutic modality remains to be established despite the great number of therapeutic trials that have been tried \[[@CR4]--[@CR6]\]. Therefore, we considered it necessary to establish a therapeutic strategy taking into account gender, age, histological findings, and laboratory characteristics.

Regarding the treatment of IgAN, Xie et al. \[[@CR7]\] reported on the efficacy of tonsillectomy in 2003. On the other hand, Pozzi et al. \[[@CR8], [@CR9]\] reported the effectiveness of steroid pulse therapy based on a series of randomized control trials in 1999 and 2004. Tonsillectomy plus steroid pulse therapy has rapidly spread in Japan. Recently, Kawamura et al. \[[@CR10]\] proposed the domestic clinical guidelines for IgAN in Japan, v. 3 (referred to hereafter as CGJ-IgAN) in which dialysis induction risk groups were stratified by prognostic grades that took into account histological as well as clinical severities (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).Table 1Classification of clinical severity of IgANClinical severityUrinary protein (g/day)eGFR (ml/min/1.73 m^2^)C-grade I\<0.5--C-grade II≥0.5≥60C-grade III≥0.5\<60*eGFR* estimated glomerular filtration rate (ml/min/1.73 m^2^)Table 2Classification of pathologic severity of IgANPathologic severityNumber of glomeruli with global sclerosis + segmental lesion/total number of glomeruli (%)Acute lesions onlyAcute + chronic lesionsChronic lesions onlyH-grade I0--24.9 AA/CCH-grade II25--49.9 AA/CCH-grade III50--74.9 AA/CCH-grade IV≥75AA/CCAcute lesion (A): cellular crescent, fibrocellular crescent, glomerular capillary necrosis, chronic lesion (C): nodular sclerosis, segmental glomerulosclerosis, fibrous crescent, segmental lesion: cellular crescent, fibrocellular crescent, segmental sclerosis, fibrous crescentTable 3Dialysis induction riskH-grade IH-grade IIH-grade IIIC-grade ILowModerateHighC-grade IIModerateModerateHighC-grade IIIHighHighVery high

Proper therapeutic options for IgAN cannot be provided unless pathological diagnosis can be standardized as reliable prognostic indicators. Although such therapeutic options have not been tried, especially with angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), tonsillectomy, tonsillectomy plus oral steroids, and tonsillectomy plus steroid pulse therapy, a comparative evaluation of the long-term outcome of these therapies has not yet been performed.

This study examined the efficacy of several factors impacting long-term renal survival, such as gender, age, therapeutic option, and dialysis induction risk according to the new domestic CGJ-IgAN. Multivariate analysis was used for this study.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

Between December 1986 and July 2009, 303 patients were diagnosed with IgAN by renal biopsy at Fujita Health University and its affiliated hospitals. The diagnosis of IgAN was based on predominant mesangial IgA staining shown on immunofluorescence study. Patients with systemic diseases such as diabetes mellitus, systemic lupus erythematosus, abnormal hypergammaglobulinemia, chronic liver diseases, and Henoch-Schönlein purpura were distinguished from IgAN by clinico-pathological features. Among IgAN patients, the following patients were excluded from this study: (1) age \<15 years, (2) insufficient number of glomeruli (\<7 glomeruli) in a biopsy specimen for light microscopic study, (3) follow-up period \<18 months, (4) patients who showed a combination with other systemic diseases (antineutrophil cytoplasmic antibodies-associated vasculitis, systemic lupus erythematosus, malignancy) during an observation period, or (5) incomplete data in the medical records. As a result, 208 of the 303 patients were included in this study (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Enrollment of study patients. Detailed list of reasons for exclusion of patients

This study complied with the Helsinki declaration and was approved by the Ethics Committee of Fujita Health University (approval number 11--130).

Clinical, laboratory, and pathological analyses {#Sec4}
-----------------------------------------------

The baseline data at the time of renal biopsy were compiled from medical records. The time of renal biopsy was regarded as the entry time into the follow-up. The clinical data evaluated included gender, age, and receiving ACEIs or ARBs. The laboratory data were also evaluated, and included serum creatinine, estimated glomerular filtration rate (eGFR), and degrees of proteinuria and hematuria at (a) the time of renal biopsy, (b) the end of steroid pulse therapy, (c) the end of administration of prednisolone, and (d) the final observation time. The qualitative findings of hematuria were converted into scores as (−) to 0, (±) to 1, (1+) to 2, (2+) to 3, and (3+) to 4. The histological findings were classified according to the new histological classification of IgAN in CGJ-IgAN. The classification details are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}. The names of the patients were blinded to all evaluations of baseline data from renal biopsies.

Stratification of dialysis induction risk {#Sec5}
-----------------------------------------

Predictive grading of dialysis induction risk in the CGJ-IgAN was defined by stratification of the two grades of clinical and histological severities. The clinical severities were graded by the levels of urinary protein (UP g/day) and eGFR (ml/min/1.73 m^2^) at the time of renal biopsy. Clinical grades (C-G I--III) were defined as C-G I, UP \< 0.5; C-G II, UP ≥0.5 and eGFR ≥60; C-G III, UP ≥0.5 and eGFR \< 60 (Table [1](#Tab1){ref-type="table"}). The parameters of histological evaluation consisted of crescent formation and segmental/global glomerular sclerosis. Thus, histological severity was evaluated by the percentage of injured glomeruli in the total number of glomeruli seen in renal biopsy. Histological grades (H-G I--IV) were defined as H-G I, \<25 %; H-G II, 25--49.9 %; H-G III, 50--74.9 %; and H-G IV, ≥75 % (Table [2](#Tab2){ref-type="table"}). Cellular and fibrocellular crescents were defined as acute lesions. Global/segmental glomerulosclerosis or fibrous crescents were defined as chronic lesions. From the clinical and histological grading, dialysis induction risks were stratified and classified as low, moderate, high and very high risk groups as shown in Table [3](#Tab3){ref-type="table"}.

Treatment protocol {#Sec6}
------------------

The 208 patients in this study were divided into 4 groups based on the treatment regimens as follows: (1) tonsillectomy alone (T group), (2) tonsillectomy followed by 40 mg/day of oral prednisolone (PSL) which was gradually tapered over 2 years (TOS group), (3) tonsillectomy plus steroid pulse of intravenous methylprednisolone 500 mg/day for 3 consecutive days, generally for 4 courses every 2 months which was discontinued at 3 courses if urinary findings showed remission, followed by oral PSL at an initial dose of 20 mg/day (TSP group), and (4) no particular therapy, in which patients received neither tonsillectomy nor steroid therapy (N group). All patients were given an antiplatelet agent, antithrombotic drugs, and antihypertensive agents according to the discretion of the physician. Among all groups, the use of ACEIs or ARBs was defined as \>6 months.

Statistical analysis {#Sec7}
--------------------

The endpoint of renal survival was set as doubled creatinine levels compared with values at the time of renal biopsy. Cox's proportional hazards model was used to explore the multiple covariates for renal survival. All continuous variables are presented as mean ± SD. Baseline clinical data among the groups were compared using the Kruskal--Wallis test, unpaired *t* test, and Mann--Whitney *U* test as appropriate for continuous data, and the Chi-squared statistic for categorical data. Cox's regression proportional hazards model was used to estimate the relative risks associated with the baseline covariates of gender, age, histological activity, the dialysis induction risk, therapeutics, and the use of ACEIs or ARBs. A backward stepwise method was used to select the significant covariates. *P* \< 0.05 was used to reject the null hypothesis of no statistical difference between-groups. For the comparison of four groups, Dunn's test was performed. A *P* value \< 0.0083 was considered statistically significant, as indicated by asterisks in the tables. All of the analyses were made using SPSS statistical software for Windows, release Ver.18.

Results {#Sec8}
=======

Study population {#Sec9}
----------------

The clinical features of the patients are shown in Table [4](#Tab4){ref-type="table"}. The mean duration of follow up was 88.5 months in the 208 patients (median 76 months, range 18--288 months). The mean age was 35.1 years. The male:female ratio was 1:1. At the time of renal biopsy, mean proteinuria was 1.32 ± 1.50 (SD) g/day. Severe proteinuria (\>3.5 g/day) was observed in 10 patients (4.8 %). During the follow-up period, 154 (74.0 %) of the 208 patients were given ACEIs or ARBs. Among the four therapy groups, there were significant differences in eGFR (*P* = 0.001), proteinuria (*P* \< 0.001), the dialysis induction risk (*P* = 0.001), and observation period (*P* \< 0.001). No difference was observed in the sex ratio, age, hematuria, and use of ACEIs or ARBs. eGFR was significantly lower in the TSP group than in the T and TOS groups. Proteinuria was significantly higher in both TOS and TSP groups than in the T and N groups. The distribution of patients for dialysis induction risk was significantly different among the four groups, with the T and TOS groups having more patients with low risk than the TSP groups.Table 4(a) Baseline characteristics and (b) distribution of 208 patients with IgA nephropathyT groupTOS groupTSP groupN group*P* valueTotal(a) Number of patients56334772208 Sex (male/female)27/2917/1620/2740/320.568104/104 Age (years)32.7 ± 13.531.4 ± 11.134.4 ± 11.039.1 ± 15.30.25035.1 ± 13.7 Serum creatinine (mg/dl)0.85 ± 0.300.80 ± 0.201.03 ± 0.431.04 ± 0.550.3800.95 ± 0.43 eGFR (ml/min)84.4 ± 27.586.5 ± 24.167.8 ± 26.7\*72.0 ± 32.30.00176.7 ± 29.6 Proteinuria (g/day)1.05 ± 1.351.71 ± 1.46\*\*1.87 ± 2.12\*\*0.98 ± 0.86\<0.0011.32 ± 1.50 Hematuria3.4 ± 1.13.7 ± 0.63.4 ± 1.03.2 ± 1.10.3733.4 ± 1.0 Dialysis induction risk (low:moderate:high:very high)17:29:5:53:27:2:15:19:9:14\*18:23:17:140.00143:98:33:34 Hypertension (yes/no)75.0 (42/14)81.8 (27/6)78.7 (37/10)79.2 (57/15)0.88874.0 (163/45) Use of ACEIs or ARBs (%) (use/no use)69.6 (39/17)78.8 (26/7)76.6 (36/11)73.6 (53/19)0.77474.0 (154/54) Observation period (months)102.9 ± 51.4122.0 ± 50.053.8 ± 38.1\*\*\*84.6 ± 56.8\<0.00188.5 ± 55.3 Median (months)100 (24--288)108 (40--208)42 (18--204)\*\*\*66 (18--258)\*\*\*\*76 (18--288)(b) Histological grade (I:II:III:IV)40:10:4:224:8:1:015:14:11:7\*37:15:11:9\<0.001116:47:27:18 Clinical grade (I:II:III)18:29:93:27:38:20:19^†^22:25:250.04851:101:56 Histological activity (A:A/C:C)5:10:41^‡^5:16:122:36:92:21:49^‡^\<0.00114:83:111Data shown as mean ± SD or frequencies. Hematuria were converted into scores as (−) to 0, (±) to 1, (1 +) to 2, (2 +) to 3, and (3 +) to 4. N group patients received neither tonsillectomy nor steroid therapy*eGFR* estimated glomerular filtration rate (ml/min/1.73 m^2^), *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin-II receptor blocker, *T group* tonsillectomy alone, *TOS group* tonsillectomy + oral PSL, *TSP group* tonsillectomy + steroid pulse, *N group* no particular therapy\* Significantly different versus T and TOS groups, \*\* significantly different versus T and N groups, \*\*\* significantly different versus T, TOS, and N groups, \*\*\*\* significantly different versus TOS group, ^†^ significantly different versus T group, ^‡^ significantly different versus TOS and TSP groups

Clinical outcomes {#Sec10}
-----------------

At the final observation, 5 (8.9 %) patients in the T group, 2 patients (6.1 %) in the TOS group, 1 patient (2.1 %) in the TSP group, and 22 patients (30.6 %) in the N group had reached the endpoint of a doubled creatinine concentration since the time of renal biopsy (Table [5](#Tab5){ref-type="table"}). Table [6](#Tab6){ref-type="table"} shows the eGFRs and urinary protein levels at the times of renal biopsy and at the final observation in each of the 4 groups. The levels of eGFR were significantly decreased in T, TOS, and N groups but not in the TSP group. Except for the N group, urinary protein levels were significantly improved at the final observation. Especially in the steroid therapy groups (TOS and TSP) the average daily urinary protein excretion decreased from \>1.5 to \<0.5 g/day.Table 5Outcome of treatment in the each groupDoubling serum creatinine (%)T group5/56 (8.9)TOS group2/33 (6.1)TSP group1/47 (2.1)N group22/72 (30.6)*PSL* prednisolone, *T group* tonsillectomy alone, *TOS group* tonsillectomy + oral PSL, *TSP group* tonsillectomy + steroid pulse, *N group* no particular therapyTable 6(a) eGFR and (b) proteinuria in each groupAt renal biopsyFinal observation*P* value(a) eGFR (ml/min) T group84.4 ± 27.572.5 ± 29.6\<0.001 TOS group86.5 ± 24.177.3 ± 27.60.006 TSP group67.8 ± 26.767.7 ± 26.0ns N group72.0 ± 32.354.5 ± 38.0\<0.001(b) Proteinuria (g/day) T group1.05 ± 1.350.49 ± 1.16\<0.001 TOS group1.71 ± 1.460.25 ± 0.33\<0.001 TSP group1.87 ± 2.120.42 ± 0.80\<0.001 N group0.98 ± 0.861.07 ± 1.65ns*eGFR* estimated glomerular filtration rate (ml/min/1.73 m^2^), *ns* no significant difference, *T group* tonsillectomy alone, *TOS group* tonsillectomy + oral PSL, *TSP group* tonsillectomy + steroid pulse, *N group* no particular therapy

Risk factors for the development of renal failure {#Sec11}
-------------------------------------------------

Multivariate hazard ratios for the doubling of serum creatinine levels are shown in Table [7](#Tab7){ref-type="table"}(a). Both gender (male) and age (\>40 years) were significant factors in the development of renal failure (*P* \< 0.05 for both). Conversely, there was no difference in whether or not ACEIs or ARBs were used. The hazard ratio (HR) for the doubling of serum creatinine levels in histologically judged acute + chronic lesions was 2.53 (95 % CI 1.03--6.17) (*P* \< 0.05) and significantly higher than chronic lesions alone. On the other hand, histological findings of acute lesions did not affect the risk of doubling serum creatinine levels. For analysis of the efficacy of the dialysis induction risk, we conducted univariate analysis about each parameter (eGFR, urinary protein, histological grade). eGFR, urinary protein and histological grade were significant factors in the development of renal failure \[Table [7](#Tab7){ref-type="table"}(b)\]. In the patients in the very high dialysis induction risk group the HR of doubling the serum creatinine level was 12.50, which was also significantly higher than the moderate risk group (*P* \< 0.01). The low and high dialysis induction risk patients showed no difference to the moderate risk patients. As for the therapeutics, the HR of the T and TSP groups were 0.314 (0.11--0.93) and 0.032 (0.00--0.28), respectively, compared to the N group (*P* \< 0.05, \< 0.01). The HR for doubling serum creatinine levels of the TOS group showed no difference with the N group \[HR 0.213 (0.04--1.10), *P* = 0.065\].Table 7(a) Multivariate-adjusted and (b) univariate hazard ratios for development of 100 % increase of serum creatinine*B*Standard errorWald*P* valueHR95 % CI(a)Male (vs. female)1.0130.4594.8760.0272.761.22--6.77 Age (vs. ≤40 years)1.0750.4196.5770.0102.931.29--6.66Histological activity (chronic)1 (reference) Acute−10.023429.6840.0010.981\<0.0010.00-- \<1000 Acute + chronic0.9260.4564.1230.0422.531.03--6.17Dialysis induction risk (moderate)1 (reference) Low risk−11.481205.7560.0030.956\<0.001-- High risk1.0030.5872.9160.0882.730.86--8.61 Very high risk2.5260.54021.8600.00012.504.34--36.0Method of therapy (N)1 (reference) T group−1.1590.5544.3720.0370.3140.11--0.93 TOS group−1.5450.8373.4100.0650.2130.04--1.10 TSP group−3.4491.1149.5880.0020.0320.00--0.28 Use of ACEI or ARB (vs use)0.9560.5223.3550.0672.600.94--7.24(b) eGFR  \> 60 ml/min/1.73 m^2^1 (reference)  \<60 ml/min/1.73 m^2^1.9920.40524.206\<0.0007.333.31--16.2 Urinary protein \< 0.5 g/day1 (reference)  \>0.5 g/day2.2271.0294.6860.0309.291.23--69.7Histological grade (I)1 (reference)  II1.4240.5885.8700.0154.161.31--13.2  III2.0310.56113.127\<0.0007.622.54--22.9  IV2.9160.56326.851\<0.00018.476.13--66.7*PSL* prednisolone, *TSP group* tonsillectomy + steroid pulse, *N* no particular therapy, *T* tonsillectomy alone, *TOS group* tonsillectomy + oral PSL, *ACEI* angiotensin-converting enzyme inhibitor, *ARB* angiotensin-II receptor blocker, *eGFR* estimated glomerular filtration rate (ml/min/1.73 m^2^)

Adverse effect {#Sec12}
--------------

Three patients developed steroid-induced psychosis (one in TOS group, two in TSP group). Three patients developed diabetes mellitus and required insulin (one in TOS group, two in TSP group) and received treatment. One patient in the N group died of pneumonia before the endpoint. No patient had any serious side-effect such as aseptic necrosis of femoral bone.

Discussion {#Sec13}
==========

The purpose of this study was to clarify effects of each treatment method on long-term renal survival in adult IgAN patients. To our knowledge, there is no report available from a single institution that compares long-term renal survival among the above treatment methods in adult patients with IgAN. In our institution, tonsillectomy has been performed for patients with IgAN for 25 years. In our institute, TSP therapy was started in 2003. Before 2002, there were no definite criteria of the selection of the treatments (T, TOS, and N). From 2003, we informed the patients of treatment with N, T, and TSP. We recommended TSP to patients if they had urinary protein \> 0.5 g/day continuously. However, we also accepted the desire of patients who wished to receive TSP or tonsillectomy. Treatment methods have been applied to cases of various degrees of severity, providing us with a sufficient number of study patients. We employed the technique of multivariate analysis to assess the impact of multiple covariates for long-term renal survival (and to exclude potential bias).

Gender (male), age (≥40 years), histologically acute + chronic region, dialysis induction risk, and therapeutic option significantly affected renal survival. Conversely, use of ACEIs or ARBs did not influence renal survival. A noteworthy result of our study was that tonsillectomy alone significantly contributed to preservation of renal function. This was proved by comparing the T and N groups, both of which did not have a significant difference in clinical and laboratory data (Table [4](#Tab4){ref-type="table"}).

Regarding steroid therapy for IgAN, Kobayashi et al. \[[@CR11]\] first reported on its efficacy. Hotta et al. reported the absence of progressive renal dysfunction in 157 IgAN patients that went into so-called 'clinical remission' out of 529 patients. Furthermore, they were free of urinary findings after follow-up of ≥ 36 months (average follow-up 82.3 months). Remission was significantly correlated with tonsillectomy and steroid pulse therapy, indicating that it was a potential standard therapy to induce clinical remission \[[@CR12]\]. Recently long-term follow-up studies conducted over 10 years were reported concerning the efficacy of tonsillectomy in IgA nephropathy. Akagi et al. \[[@CR13]\] and Xie et al. \[[@CR4]\] reported that the tonsillectomy group 'preserved renal function' more efficiently than in the non-tonsillectomy group. In Japan where health checkup systems are quite advanced, it is relatively easy to detect early-stage IgAN. Therapeutic interventions such as tonsillectomy, when initiated in early-stage IgAN, are expected to preserve the kidney for a longer period. Moreover, our results showing the inhibitory effect of tonsillectomy on progress of IgAN supports the idea that tonsillectomy alone significantly prolonged survival time of the kidney.

According to Katafuchi et al. \[[@CR14]\] steroid pulse therapy significantly inhibited the progress of IgAN to terminal renal failure as compared to both non-steroid and oral steroid therapies. These observations were supported by our current study. TSP had the highest impact on inhibiting progression of IgAN. From this observation, it was suggested that tonsillectomy plus steroid pulse therapy was an efficacious therapy to preserve renal function. However, the data of our study provided limited information because this was a retrospective study.

In conclusion, combination therapies of tonsillectomy and steroid pulse had the most significant therapeutic impact compared to other therapies. Multivariable analysis also showed that gender, age, histological activity and the dialysis induction risk were associated with the progression of IgAN.

None.
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